BI-9627 is a potent and selective agonist of the GPR35 receptor, making it a valuable tool compound in pharmacological research focused on metabolic and inflammatory diseases. It has been primarily used in preclinical studies to investigate the role of GPR35 in glucose homeostasis, insulin secretion, and gastrointestinal motility. Due to its ability to activate signaling pathways involved in insulin release, BI-9627 shows potential for studying type 2 diabetes and related metabolic disorders. Additionally, its activity in immune cells suggests relevance in researching inflammatory conditions such as colitis and other gastrointestinal diseases. Its selectivity and potency make it suitable for target validation and mechanistic studies in both in vitro and in vivo models.